Compliance on Directly Acting Oral Antiviral in Hcv Patients

INTRODUCTION: Chronic hepatitis C is one of the most common cause all over the world for causing cirrhosis of liver and thus requiring liver transplantation as the definitive treatment which is beyond reach in most of patients in developing countries. The availability of oral directly acting antiviral for treatment in India since 2015 has changed the scenario due to its good compliance among the patients. AIMS AND OBJECTIVES: To determine the compliance among patients who were treated with directly acting oral antiviral drugs for Hepatitis C (Sofosbuvir 400 mg, Daclastavir 60 mg, Velpatasvir 100 mg). MATERIALS AND METHODS: It was prospective study conducted at Department of Medical Gastroenterology, Post Graduate Institute of Medical Sciences (PGIMS), Rohtak, over a period of five years from 01.01.2016 to 31.12.2020. Out of four thousand patients of Chronic hepatitis C who reported in department in above five years duration, 570 patients pre therapy HCV RNA was not detected, hence they were not treated and were not part of the study. Out of the remaining 3430 patients, 130 patients went for alternative medications and hence were excluded from the study. The remaining 3300 confirmed patients of Chronic hepatitis C who were started on treatment with oral antiviral drugs were followed till they completed their treatment. Out of these 3300 patients,10 patients who were cirrhotic died during their course of treatment, hence in final analysis 3290 patients were included. RESULTS: Only ten patients out of total pool of 3290 left medicines due to side effects, thus high compliance rate of 99.69% was achieved.